Michele Stanislaw Milella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michele Stanislaw Milella has a total of 312 co-authors. Here are the top co-authors by number of shared publications:
- Daniele Caprioli
Department of Physiology and Pharmacology Sapienza University of Rome Rome Italy
4 shared publications Gabriella Vivino
Poison Control Centre Unit - Policlinico Umberto I Hospital-Sapienza University, viale del Policlinico 155, 00185, Rome, Italy; Department of Emergency, Anesthesia and Critical Care Medicine, Policlinico Umberto I Hospital-Sapienza University, viale del Policlinico 155, 00185, Rome, Italy
4 shared publicationsFrancesco Pugliese
Department of Emergency, Anesthesia and Critical Care Medicine, Policlinico Umberto I Hospital-Sapienza University, viale del Policlinico 155, 00185, Rome, Italy
3 shared publications- Ginevra D'OTtavio
National Institute on Drug Abuse, Intramural Research Program
3 shared publications - Giuseppe Procopio
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
3 shared publications - Aldo Badiani
Department of Psychology, University of Sussex, UK
2 shared publications
Latest Publications
- Open Access
Translating human drug use patterns into rat models: exploring spontaneous interindividual differences via refined drug self-administration procedures
Heroin and cocaine users tailor their dosage and frequency of use, as well as their method of administration, to maximize the drugs’ pleasurable effects and prevent withdrawal symptoms. On the other hand, many preclinical self-administration and choice experiments employ fixed unit doses and mandatory timeouts after doses (known as discrete dimension procedures). These restrictions fail to consider the distinct pharmacokinetic properties of heroin and cocaine, leading to uniform and comparable behaviors (including drug-taking patterns). This uniformity contrasts sharply with the significantly different ways humans use heroin and cocaine, which are characterized by highly individualized drug use behaviors. Here, we introduce a no-timeout procedure that overcomes this limitation (continuous dimension procedure). We analyzed the heroin and cocaine taking- and seeking-patterns and estimated drug-brain levels in the presence or absence of timeout between drug injections. We further assessed how absence of timeout and the availability of drug or social peer (access time to the two rewards) affect drug preference. Removing the timeout had a profound effect on pattern of heroin taking and seeking, promoting the emergence of burst-like drug intake and social withdrawal as revealed by a discrete choice procedure. On the other hand, timeout removal had a lesser impact on cocaine taking and seeking and did not impact social preference. By removing timeout during self-administration and increasing the access time during choice resulted in a self-administration procedure that more closely mimic human heroin intake, offering a platform to identify novel medications.
Open AccessTranslating human drug use patterns into rat models: exploring spontaneous interindividual differences via refined drug self-administration procedures
Heroin and cocaine users tailor their dosage and frequency of use, as well as their method of administration, to maximize the drugs’ pleasurable effects and prevent withdrawal symptoms. On the other hand, many preclinical self-administration and choice experiments employ fixed unit doses and mandatory timeouts after doses (known as discrete dimension procedures). These restrictions fail to consider the distinct pharmacokinetic properties of heroin and cocaine, leading to uniform and comparable behaviors (including drug-taking patterns). This uniformity contrasts sharply with the significantly different ways humans use heroin and cocaine, which are characterized by highly individualized drug use behaviors. Here, we introduce a no-timeout procedure that overcomes this limitation (continuous dimension procedure). We analyzed the heroin and cocaine taking- and seeking-patterns and estimated drug-brain levels in the presence or absence of timeout between drug injections. We further assessed how absence of timeout and the availability of drug or social peer (access time to the two rewards) affect drug preference. Removing the timeout had a profound effect on pattern of heroin taking and seeking, promoting the emergence of burst-like drug intake and social withdrawal as revealed by a discrete choice procedure. On the other hand, timeout removal had a lesser impact on cocaine taking and seeking and did not impact social preference. By removing timeout during self-administration and increasing the access time during choice resulted in a self-administration procedure that more closely mimic human heroin intake, offering a platform to identify novel medications.
- 15 February 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (2) , e5767
Self‐harm by single‐ and multi‐agent medication poisoning in a retrospective analysis of a Poison Control Center database from January 2018 to December 2022
Purpose: Medication poisoning is the most common method of self‐harm. Longitudinal studies incorporating pre‐ and post‐COVID‐19 pandemic data are required to describe the phenomenon and to evaluate the long‐term impact on mental health.Methods: Calls to the Poison Control Center of Policlinico Umberto I Hospital ‐ Sapienza University of Rome, Italy, were analyzed retrospectively for characteristics and clinical presentation of cases of interest from January 2018 to December 2022.Results: A total of 756 cases of self‐harm by medication poisonings were recorded in the study period. A reduction in rate of cases in 2020 was followed by a return to pre‐pandemic levels by 2021. When separately analyzing single‐ and multi‐agent cases, occurrence of cases involving just one medication increased since early 2021, with a peak in 2022 (7.8% of total calls, 95% CI 6.2–9.5, from 4.9%, 95% CI 4.1–5.8 in 2018). This increase in the rate of cases, mostly of none or mild severity, was driven by youth aged 12–21, in which the relative proportion of single‐ versus multi‐agent cases showed an increasing trend since 2020 (from 42.6% in 2018 to 78.6% in 2022). Acetaminophen was the medication most frequently involved and benzodiazepines the largest class. A psychiatric background was increasingly seen in 2022, especially in age group 12–21.Conclusion: Single‐agent medication self‐harm may be an increasingly prevailing phenomenon. Young adolescents with a psychiatric background might be most vulnerable to this behavior in the COVID‐19 pandemic aftermath. Healthcare professionals should expect favorable clinical outcome and improve both counseling and psychotherapy supervision in individuals at risk.
- 15 February 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (2) , e5767
Self‐harm by single‐ and multi‐agent medication poisoning in a retrospective analysis of a Poison Control Center database from January 2018 to December 2022
Purpose: Medication poisoning is the most common method of self‐harm. Longitudinal studies incorporating pre‐ and post‐COVID‐19 pandemic data are required to describe the phenomenon and to evaluate the long‐term impact on mental health.Methods: Calls to the Poison Control Center of Policlinico Umberto I Hospital ‐ Sapienza University of Rome, Italy, were analyzed retrospectively for characteristics and clinical presentation of cases of interest from January 2018 to December 2022.Results: A total of 756 cases of self‐harm by medication poisonings were recorded in the study period. A reduction in rate of cases in 2020 was followed by a return to pre‐pandemic levels by 2021. When separately analyzing single‐ and multi‐agent cases, occurrence of cases involving just one medication increased since early 2021, with a peak in 2022 (7.8% of total calls, 95% CI 6.2–9.5, from 4.9%, 95% CI 4.1–5.8 in 2018). This increase in the rate of cases, mostly of none or mild severity, was driven by youth aged 12–21, in which the relative proportion of single‐ versus multi‐agent cases showed an increasing trend since 2020 (from 42.6% in 2018 to 78.6% in 2022). Acetaminophen was the medication most frequently involved and benzodiazepines the largest class. A psychiatric background was increasingly seen in 2022, especially in age group 12–21.Conclusion: Single‐agent medication self‐harm may be an increasingly prevailing phenomenon. Young adolescents with a psychiatric background might be most vulnerable to this behavior in the COVID‐19 pandemic aftermath. Healthcare professionals should expect favorable clinical outcome and improve both counseling and psychotherapy supervision in individuals at risk.
- Open Access
- 8 April 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-16
Heroin and its metabolites: relevance to heroin use disorder
Heroin is an opioid agonist commonly abused for its rewarding effects. Since its synthesis at the end of the nineteenth century, its popularity as a recreational drug has ebbed and flowed. In the last three decades, heroin use has increased again, and yet the pharmacology of heroin is still poorly understood. After entering the body, heroin is rapidly deacetylated to 6-monoacetylmorphine (6-MAM), which is then deacetylated to morphine. Thus, drug addiction literature has long settled on the notion that heroin is little more than a pro-drug. In contrast to these former views, we will argue for a more complex interplay among heroin and its active metabolites: 6-MAM, morphine, and morphine-6-glucuronide (M6G). In particular, we propose that the complex temporal pattern of heroin effects results from the sequential, only partially overlapping, actions not only of 6-MAM, morphine, and M6G, but also of heroin per se, which, therefore, should not be seen as a mere brain-delivery system for its active metabolites. We will first review the literature concerning the pharmacokinetics and pharmacodynamics of heroin and its metabolites, then examine their neural and behavioral effects, and finally discuss the possible implications of these data for a better understanding of opioid reward and heroin addiction. By so doing we hope to highlight research topics to be investigated by future clinical and pre-clinical studies.
- 8 April 2023
- Published by Springer Nature in Translational Psychiatry
- Vol. 13 (1) , 1-16
Open AccessHeroin and its metabolites: relevance to heroin use disorder
Heroin is an opioid agonist commonly abused for its rewarding effects. Since its synthesis at the end of the nineteenth century, its popularity as a recreational drug has ebbed and flowed. In the last three decades, heroin use has increased again, and yet the pharmacology of heroin is still poorly understood. After entering the body, heroin is rapidly deacetylated to 6-monoacetylmorphine (6-MAM), which is then deacetylated to morphine. Thus, drug addiction literature has long settled on the notion that heroin is little more than a pro-drug. In contrast to these former views, we will argue for a more complex interplay among heroin and its active metabolites: 6-MAM, morphine, and morphine-6-glucuronide (M6G). In particular, we propose that the complex temporal pattern of heroin effects results from the sequential, only partially overlapping, actions not only of 6-MAM, morphine, and M6G, but also of heroin per se, which, therefore, should not be seen as a mere brain-delivery system for its active metabolites. We will first review the literature concerning the pharmacokinetics and pharmacodynamics of heroin and its metabolites, then examine their neural and behavioral effects, and finally discuss the possible implications of these data for a better understanding of opioid reward and heroin addiction. By so doing we hope to highlight research topics to be investigated by future clinical and pre-clinical studies.
- Open Access
Targeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain
Neuropathic pain (NP) originates from an injury or disease of the somatosensory nervous system. This heterogeneous origin and the possible association with other pathologies make the management of NP a real challenge. To date, there are no satisfactory treatments for this type of chronic pain. Even strong opioids, the gold-standard analgesics for nociceptive and cancer pain, display low efficacy and the paradoxical ability to exacerbate pain sensitivity in NP patients. Mounting evidence suggests that chemokine upregulation may be a common mechanism driving NP pathophysiology and chronic opioid use-related consequences (analgesic tolerance and hyperalgesia). Here, we first review preclinical studies on the role of chemokines and chemokine receptors in the development and maintenance of NP. Second, we examine the change in chemokine expression following chronic opioid use and the crosstalk between chemokine and opioid receptors. Then, we examine the effects of inhibiting specific chemokines or chemokine receptors as a strategy to increase opioid efficacy in NP. We conclude that strong opioids, along with drugs that block specific chemokine/chemokine receptor axis, might be the right compromise for a favorable risk/benefit ratio in NP management.
Open AccessTargeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain
Neuropathic pain (NP) originates from an injury or disease of the somatosensory nervous system. This heterogeneous origin and the possible association with other pathologies make the management of NP a real challenge. To date, there are no satisfactory treatments for this type of chronic pain. Even strong opioids, the gold-standard analgesics for nociceptive and cancer pain, display low efficacy and the paradoxical ability to exacerbate pain sensitivity in NP patients. Mounting evidence suggests that chemokine upregulation may be a common mechanism driving NP pathophysiology and chronic opioid use-related consequences (analgesic tolerance and hyperalgesia). Here, we first review preclinical studies on the role of chemokines and chemokine receptors in the development and maintenance of NP. Second, we examine the change in chemokine expression following chronic opioid use and the crosstalk between chemokine and opioid receptors. Then, we examine the effects of inhibiting specific chemokines or chemokine receptors as a strategy to increase opioid efficacy in NP. We conclude that strong opioids, along with drugs that block specific chemokine/chemokine receptor axis, might be the right compromise for a favorable risk/benefit ratio in NP management.
- Open Access
- 4 November 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 130 (1) , 200-207
Transfer of chemicals to a secondary container, from the introduction of new labelling regulation to COVID‐19 lockdown: A retrospective analysis of exposure calls to the Poison Control Centre of Rome, Italy, 2017–2020
The transfer of a chemical product from its original container to an unlabelled secondary container by consumers is a potential health hazard that may result in unintentional exposures and intoxications. The aim of this study was to describe the pattern of prevalence of exposures to transferred products in Italy from year 2017, when the new European labelling regulation for chemicals became fully operative, to 2020, year of the coronavirus 19 disease first outbreak. Calls to the Poison Control Centre (PCC) of Policlinico Umberto I Hospital - Sapienza University of Rome were analysed retrospectively for characteristics, clinical presentation and circumstances related to the event. We registered 198 cases of interest. There was a reduction in cases from 2017 (4.9%) to 2019 (2.2%), followed by an increased prevalence in 2020 (4.2%) mainly due to the months “post-lockdown”. The transferred product was very frequently diluted and an empty drinking bottle was usually used as secondary container. Exposures were mostly of minor severity and no deaths occurred. The study highlights the importance of PCCs data in the evaluation of the hazard communication to users through labels, and advises for public campaigns to promote safe behaviours during future lockdowns to prevent exposures at a later period.
- 4 November 2021
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 130 (1) , 200-207
Open AccessTransfer of chemicals to a secondary container, from the introduction of new labelling regulation to COVID‐19 lockdown: A retrospective analysis of exposure calls to the Poison Control Centre of Rome, Italy, 2017–2020
The transfer of a chemical product from its original container to an unlabelled secondary container by consumers is a potential health hazard that may result in unintentional exposures and intoxications. The aim of this study was to describe the pattern of prevalence of exposures to transferred products in Italy from year 2017, when the new European labelling regulation for chemicals became fully operative, to 2020, year of the coronavirus 19 disease first outbreak. Calls to the Poison Control Centre (PCC) of Policlinico Umberto I Hospital - Sapienza University of Rome were analysed retrospectively for characteristics, clinical presentation and circumstances related to the event. We registered 198 cases of interest. There was a reduction in cases from 2017 (4.9%) to 2019 (2.2%), followed by an increased prevalence in 2020 (4.2%) mainly due to the months “post-lockdown”. The transferred product was very frequently diluted and an empty drinking bottle was usually used as secondary container. Exposures were mostly of minor severity and no deaths occurred. The study highlights the importance of PCCs data in the evaluation of the hazard communication to users through labels, and advises for public campaigns to promote safe behaviours during future lockdowns to prevent exposures at a later period.
- Open Access
- 27 April 2021
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 17 (3) , 250-256
How COVID-19 Lockdown in Italy Has Affected Type of Calls and Management of Toxic Exposures: a Retrospective Analysis of a Poison Control Center Database From March 2020 to May 2020
Introduction Between early March 2020 and the end of May 2020, Italy issued strict measures to limit further spread of coronavirus disease 2019 (COVID-19) and became the first European country that imposed a lockdown on the population. The aim of this study was to assess the impact of these restricted conditions on the activity of the Poison Control Center (PCC) of Policlinico Umberto I Hospital-Sapienza University of Rome. Methods This was a retrospective analysis of calls received by the PCC during the lockdown period March 9, 2020 through May 31, 2020 compared to the same time period in year 2019 (reference). Results We observed a reduction in calls from hospitals and emergency departments and an increase in calls from private citizens about exposures to products or intoxications during the lockdown. There were increases in unintentional exposures and exposures to hand and surface sanitizers among household and cleaning products. There was a decrease in calls concerning medications, which were mostly from hospitals and emergency departments. We observed increases in exposures requiring clinical observations among adults and referral to the emergency department among pre-school children. Conclusions Public health protection measures against COVID-19 to improve hygiene and maintain clean environments can increase exposures to hazardous products in the domestic environment. We observed an increase in unintentional exposures to household and cleaning products during the lockdown and an increase in ED referrals for pre-school children compared to the previous year. Our data suggest the need for improvements in public campaigns that promote safer handling of household products and prevent unnecessary exposures during a lockdown. The public health promotion activity can benefit the community after the pandemic and prepare the community for lockdowns in the future.
- 27 April 2021
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 17 (3) , 250-256
Open AccessHow COVID-19 Lockdown in Italy Has Affected Type of Calls and Management of Toxic Exposures: a Retrospective Analysis of a Poison Control Center Database From March 2020 to May 2020
Introduction Between early March 2020 and the end of May 2020, Italy issued strict measures to limit further spread of coronavirus disease 2019 (COVID-19) and became the first European country that imposed a lockdown on the population. The aim of this study was to assess the impact of these restricted conditions on the activity of the Poison Control Center (PCC) of Policlinico Umberto I Hospital-Sapienza University of Rome. Methods This was a retrospective analysis of calls received by the PCC during the lockdown period March 9, 2020 through May 31, 2020 compared to the same time period in year 2019 (reference). Results We observed a reduction in calls from hospitals and emergency departments and an increase in calls from private citizens about exposures to products or intoxications during the lockdown. There were increases in unintentional exposures and exposures to hand and surface sanitizers among household and cleaning products. There was a decrease in calls concerning medications, which were mostly from hospitals and emergency departments. We observed increases in exposures requiring clinical observations among adults and referral to the emergency department among pre-school children. Conclusions Public health protection measures against COVID-19 to improve hygiene and maintain clean environments can increase exposures to hazardous products in the domestic environment. We observed an increase in unintentional exposures to household and cleaning products during the lockdown and an increase in ED referrals for pre-school children compared to the previous year. Our data suggest the need for improvements in public campaigns that promote safer handling of household products and prevent unnecessary exposures during a lockdown. The public health promotion activity can benefit the community after the pandemic and prepare the community for lockdowns in the future.
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3552
Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study
- 15 November 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (11) , e3552
Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study
- Open Access
- 1 September 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 62, 64-71
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
- 1 September 2017
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 62, 64-71
Open AccessHCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
- 28 July 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (10) , 1166-1169
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents
- 28 July 2017
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (10) , 1166-1169
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents